In this study, the eficacy and safety of sumatriptan, a selective 5-HT1-like receptor agonist, were studied in 97 patients suffering a mild to severe migrain attacks. The patients were seperated in two groups, 63 patients treated with subcutaneous sumatriptan and 34 patients treated with placebo. In headache severity, 89 % of patients with sumatriptan achieved meaningful relief compared with 27 % treated with placebo at 2 hours (P< .001). Migraine-associated symptoms such as nausea, photophia, and phonophobia were significantly reduced in the sumatriptan group (P< .001). Sumatriptan was generally well-tolerated, despite being associated with more adverse events than placebo, because most adverse events were minor and transient in nature. For this reason, we have consedered that subcutaneous sumatriptanis an effective and safety treatment for migraine attacks.